

































0Vaccine 33 (2015) 465–471
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
escue  of  a  vaccine  strain  of  peste  des  petits  ruminants  virus:
n  vivo  evaluation  and  comparison  with  standard  vaccine
urali  Munirajua,  Mana  Mahapatraa,  Hubert  Buczkowskib, Carrie  Battena,
shley  C.  Banyardb,∗∗, Satya  Paridaa,∗
The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey GU24 0NF, UK
Animal and Plant Health Agency, Weybridge, Surrey KT15 3NB, UK
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 31 August 2014
eceived in revised form 17 October 2014
ccepted 24 October 2014







a  b  s  t  r  a  c  t
Across  the  developing  world  peste  des  petits  ruminants  virus  places  a huge  disease  burden  on agricul-
ture,  primarily  affecting  the  production  of  small  ruminant.  The  disease  is most  effectively  controlled  by
vaccinating  sheep  and  goats  with  live  attenuated  vaccines  that  provide  lifelong  immunity.  However,  the
current  vaccines  and  serological  tests  are  unable  to enable  Differentiation  between  naturally  Infected
and  Vaccinated  Animals  (DIVA).  This  factor  precludes  meaningful  assessment  of  vaccine  coverage  and
epidemiological  surveillance  based  on  serology,  in  turn  reducing  the  efﬁciency  of control  programmes.
The  availability  of  a recombinant  PPRV  vaccine  with  a proven  functionality  is a prerequisite  for  the  devel-
opment  of  novel  vaccines  that  may  enable  the development  of  DIVA  tools  for PPRV  diagnostics.  In  this
study,  we  have  established  an  efﬁcient  reverse  genetics  system  for PPRV  Nigeria  75/1  vaccine  strain  and,
further rescued  a version  of  PPRV  Nigeria  75/1  vaccine  strain  that  expresses  eGFP  as  a novel  transcription
cassette  and  a version  of PPRV  Nigeria  75/1  vaccine  strain  with  mutations  in the haemagglutinin  (H)  genen vivo evaluation to  enable  DIVA  through  disruption  of  binding  to H by the  C77 monoclonal  antibody  used  in the  compet-
itive  (c)  H-ELISA.  All  three  rescued  viruses  showed  similar  growth  characteristics  in vitro in comparison
to  parent  vaccine  strain  and, following  in  vivo  assessment  the  H mutant  provided  full  protection  in goats.
Although  the  C77 monoclonal  antibody  used  in  the cH-ELISA  was unable  to bind to the  mutated  form  of
H  in vitro,  the  mutation  was  not  sufﬁcient  to  enable  DIVA  in  vivo.
© 2014  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Peste des petits ruminants (PPR) is an important infectious viral
isease of domestic and wild small ruminants that threatens the
ood security and sustainable livelihood of farmers across Africa,
he Middle East and Asia [1,2]. PPR is emerging in new regions of
he world and is causing great economic losses [3]. The causative
gent, peste des petits ruminants virus (PPRV) belongs to the family
aramyxoviridae, genus morbillivirus [4] alongside other important
iral pathogens such as rinderpest virus (RPV), measles virus (MeV)
nd canine distemper virus (CDV). The morbillivirus genome is
round 16 kbp, and encodes a nucleoprotein (N), phosphoprotein
P), matrix protein (M), fusion protein (F), haemagglutinin protein
H) and a large polymerase (L) protein. The N, F and H proteins are
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the most immunogenic and following infection virus neutralising
antibodies are generated against the H and F glycoproteins whilst a
poorly neutralising response is seen to the N protein. The live atten-
uated vaccine strain PPRV Nigeria 75/1 has been used successfully
in the ﬁeld for decades [5]. The commercially available diagnos-
tic ELISAs are targeted against the N and H proteins and detect
antibodies in vaccinated as well as naturally infected animals. No
tools currently exist that allow serological Differentiation between
Infected and Vaccinated Animals (DIVA). To this end, marker vac-
cines are a potential solution to the DIVA concept that may  play an
important role in the reduction of PPRV in endemic regions.
Existing DIVA strategies for PPRV have focussed on developing
protein subunit vaccines expressing the PPRV F and or H gene in
viral vectors like pox viruses (vaccinia, capripox and fowl pox) and
adenoviruses (canine or human type) [6–12]. Here the absence of
the PPRV N protein in the vaccine preparation facilitates positive
serological identiﬁcation of infected animals. However, such sub-
unit vaccines often require multiple doses and may have reduced
efﬁcacy due to: potential pre-existing immunity to the viral vec-
tor; reduced antibody induction through an inability to replicate;
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he potential for short lived antibody responses; potentially high
osts of recombinant vaccine production. An alternative strategy is
o use the existing live attenuated PPRV vaccine and manipulate a
peciﬁc region or epitope of a viral protein to obtain positively and
r negatively marked vaccines. Reverse genetics provides a means
o manipulate RNA virus genomes through DNA copies (cDNA) of
he RNA genome. In this study, a reverse genetics system for PPRV
igeria 75/1 vaccine strain was established successfully with recov-
ry of virus from cDNA. Further, we have generated a positively
arked vaccine by generating a recombinant virus expressing eGFP
s a novel transcription cassette. Furthermore we have attempted
o negatively mark the vaccine by creating a recombinant that
s epitope deleted for part of the anti PPRV H C77 monoclonal
ntibody binding site, a key component of the current diagnostic
ompetitive H ELISA (c-HELISA). The negatively marked rescued
irus was assessed in goats to investigate protection when com-
ared to existing vaccine preparations and to assess DIVA potential.
. Materials and methods
.1. Cells culture
VeroDogSLAMtag (VDS) cells [13] were used for virus rescue
nd propagation. Cells were cultured in Dulbecco’s modiﬁed Eagle’s
edium supplemented with 5% (v/v) foetal calf serum (FCS, Gibco)
nd penicillin (100 U/ml, Sigma) at 37 ◦C/5% CO2.
All viruses were rescued and grown in VDS cells until the detec-
ion of cytopathic effect (CPE) before being freeze-thawed, clariﬁed
nd stored at −70 ◦C. The Nigeria 75/1 vaccine was  obtained
ommercially (The Pirbright Institute, UK). Final virus titre was
etermined by 50% tissue culture infectious dose (TCID50) as
escribed previously [14].
.2. Phage display peptide library screening for C77 mAb binding
pitope
Anti-PPRV-H C77 monoclonal antibody (mAb) derived from a
ybridoma line was puriﬁed from cell culture supernatant using
he Melon Gel Monoclonal IgG Puriﬁcation Kit (Pierce). Puriﬁed C77
as dialysed against 0.1 M NaHCO3 (pH 8.6) and its concentration
easured using a BCA Protein Assay Kit (Pierce) [15]. The Ph.D.-
2TM Phage Display Peptide Library Kit (New England BioLabs) was
sed to screen for C77 binding epitopes as described previously
15]. Data obtained from several rounds of panning were analysed
sing the Vector NTi software package (Invitrogen) and amino acid
equences were mapped to the native PPRV Nigeria75/1 H protein.
.3. Construction of recombinant PPRV cDNA clones
The full-length PPRV cDNA plasmids generated were based on
he PPRV Nigeria 75/1 vaccine strain (GenBank accession number
74443.2). The plasmid containing the complete PPRV antigenome
equence (15948 nt) with the insertion of eGFP gene was designed
nd synthesised commercially (DNA2.0, USA) (Fig. 1a). The eGFP
eporter gene (822 nt) was introduced to enable rapid evaluation
f rescue events, as a separate transcriptional unit between the P
nd M gene with the authentic 5′ untranslated regions (UTRs) of
he M gene and the 3′ UTR of the P gene. Novel restriction enzyme
ites were inserted by nucleotide substitution into the untranslated
egions (UTRs) of each gene and as such did not affect the total
enome length or viral protein sequences. The full length clone
as under the expression control of the T7 RNA polymerase pro-
oter and cleaved at the antigenome promoter by the hepatitis
elta ribozyme (Fig. 1a). The synthesised plasmid, pPPRV + GFP was
equenced in its entirety to ensure the sequence was 100% identi-
al to the wild type vaccine strain. After the successful recovery of 33 (2015) 465–471
a recombinant PPRV expressing the eGFP gene, the eGFP gene in
the plasmid pPPRV + GFP was removed using MluI to obtain pPPRV
(Fig. 1b). To generate a negatively marked vaccine, the C77 bind-
ing site mapped through phage display peptide library screening
(R547 S549 S550) was  altered in the plasmid pPPRV by site directed
mutagenesis (R547A S549A S550A) to obtain plasmid pPPRV-C77
(Fig. 1c and d). The epitope mapped by phase display peptide library
screening is depicted in Fig. 1d. The helper plasmids required for
rescue of recombinant viruses, PPRV Nigeria 75/1 N (pN), P (pP)
and L (pL), were cloned under the control of the T7 RNA poly-
merase promoter in the pGEM3z vector (Promega). All three full
length plasmids and helper plasmids were sequenced to ensure
that no additional mutations had been incorporated through PCR
and cloning.
2.4. Transfection and recovery of recombinant PPRV from cDNA
VDS cells (70% conﬂuent) were grown in 6-well plates and
infected with T7-polymerase expressing recombinant fowl pox
virus at a multiplicity of infection (MOI) of 0.2 as described pre-
viously [16]. Cells were washed and transfected with 1 g of
full-length PPRV cDNA plasmid and 1 g pN, 1 g pP and 0.05 g pL
using TransFastTM Transfection Reagent (Promega) at a ratio of 6:1
(wt/wt) in a total volume of 0.75 ml  of OPTI-MEM I reduced serum
medium/well (Gibco). Media was  changed on cells at 24 h post
transfection and observed for CPE for three days. Rescued viruses
were harvested by freeze thawing and further passaged in VDS cells.
2.5. In vitro characterisation of recombinant viruses
To conﬁrm the identity of rescued viruses, RT-PCR was  per-
formed using PPRV speciﬁc primers. Total RNA was extracted from
rescued viruses at the third passage and analysed by RT-PCR.
Primers were designed ﬂanking the eGFP gene and the C77 bind-
ing site and amplicons derived from each virus were sequenced
to determine the correct sequence were present. Immunoﬂores-
cence for the expression of N, H and or eGFP by the rescued viruses
was carried out by labelling the N protein with an anti-PPRV-
N C11 monoclonal antibody and the H protein with anti-PPRV-H
C77 monoclonal antibody (BDSL, UK) and GFP autoﬂuorescence
[14,17].
The in vitro growth kinetics of the recombinant PPRVs and the
parental virus was assessed in a multiple-step growth cycle as
described earlier [14,17]. To determine the stability of the inserted
eGFP transcriptional unit or the mutated C77 mAb binding site in
the recombinant virus genome, the viruses were serial passed in
VDS cells for up to nine passages and assessed for the expression
of GFP and stable mutation of C77 mAb  binding site using RT-PCR
followed by sequencing and confocal microscopy.
2.6. In vivo vaccination and challenge experiment
Animal experiments were conducted according to UK Home
Ofﬁce regulations (Project licence number: 70/6907) and following
ethical approval at The Pirbright Institute. European mixed breeds
of 12 male goats, aged 6–9 months were randomly split into three
groups (n = 4/group). Animals in group one (G1, G2, G3 and G4) were
immunised with 104 TCID50 rPPRV-C77 whilst animals in group two
(G7, G8, G9 and G10) received the PPRV Nigeria 75/1 conventional
vaccine virus (104 TCID50) via the sub-cutaneous route. Groups one
and two were housed in separate rooms along with two unvacci-
nated control animals per room (G5, G6, G11 and G12). Animals
were monitored daily for 28 days post vaccination. At four weeks
post vaccination, the control goats were segregated into a separate
room and the animals from all the three treatment groups (n = 12)
were challenged with a pathogenic PPRV Ivory Coast/89 isolate (105
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Fig. 1. Schematic representation of the PPRV recombinant plasmids and predicted epitopes for C77 monoclonal antibody binding. (a) The synthetic plasmid, pPPRV+GFP,






























Nnzyme sequences. (c) Plasmid, pPPRV-C77 incorporating mutations at R547 S549 S
onoclonal antibody binding as determined by phage display, and the mutated H 
tar  symbol. Amino acid residues mutated to alanine in plasmid pPPRV-C77 are bol
CID50) by the intranasal route using LMA® MAD  NasalTM Intranasal
ucosal Atomization Device (LMA, San Diego, USA). Animals which
eveloped severe clinical signs were humanely terminated accord-
ng to an established clinical scorecard [18].
For all animals, rectal temperatures and clinical assessments
f animals were conducted twice daily. Ocular swabs were taken
n every alternate day post vaccination and challenge to analyse
achrymal secretions of PPRV by real-time RT-PCR using PPRV N
ene primers [19]. RNA extraction was achieved using robotic
xtraction methods (MagNA Pure LC Total Nucleic Acid Isolation
it, Roche, UK) following the manufacturer’s protocols. Heparinised
lood samples were collected for virus isolation from peripheral
lood mononuclear cells (PBMCs) by co-cultivation with VDS cells
14]. Clotted blood samples were collected for the evaluation of the
erum antibody response speciﬁc to the PPRV H protein using a
PR Antibody ELISA kit (BDSL, UK) and the development of PPRV
eutralising antibodies evaluated using a virus neutralisation test
VNT) [20]. Virus neutralisation titres are expressed in log10 and
itres >3 were considered positive.
. Results
.1. Recovery and characterisation of recombinant PPRVs from
DNA clones
Infectious recombinant viruses of PPRV Nigeria 75/1, with and
ithout the eGFP (rPPRV + GFP and rPPRV, respectively) and rPPRV-
77 were rescued from cDNA. The CPE characteristic of PPRV
nfection was observed three days post transfection with 100% efﬁ-
iency. The CPE observed for all the three recombinant viruses
ppeared to be identical to that produced by the parental PPRV
igeria 75/1 vaccine strain. Total RNA isolated from the recoveredmino acid positions on the H gene. (d) The proposed epitope (upper strand) for C77
r strand). Residues critical to C77 binding are highlighted in grey and indicated by
 and underlined in lower strand.
PPRV recombinants (rPPRV + GFP, rPPRV and rPPRV-C77) at pas-
sage three were subjected to RT-PCR using PPRV genome speciﬁc
primers using a −RT as a control for carry over DNA. The expected
amplicon sizes were observed on an agarose gel and sequences
were 100% identical to each respective plasmid (data not shown).
Immunoﬂuorescent imaging demonstrated the expression of
the PPRV N and H proteins in infected cells following labelling with
speciﬁc mAbs and expression was comparable to that observed
with the commercially available vaccine virus (Fig. 2a). The H pro-
tein was  detected on the surface of infected cells whilst the N
proteins were largely localised in cell cytoplasm. The rPPRV-C77
with the mutated C77 mAb  binding site (R547A S549A S550A) was
not detected by the anti-PPRV H mAb  but virus N protein could be
visualised (Fig. 2a). The successful expression of eGFP from an addi-
tional transcriptional unit inserted within the PPRV genome was
observed through its ability to autoﬂuoresce. Multi-step growth
curves were carried out to compare the growth of the recombi-
nant viruses (rPPRV + GFP, rPPRV and rPPRV-C77) with that of the
parental vaccine strain (Nigeria 75/1) (Fig. 2b). The recombinant
PPRVs grew to a similar titre and rate to that of the parental PPRV
Nigeria 75/1 virus.
3.2. Clinical protection of goats vaccinated with rPPRV-C77 and
conventional PPR vaccine upon challenge with virulent PPRV
Following vaccination, all animals remained healthy and did
not show any vaccination-related adverse effects. Similarly, 28
days post vaccination when the goats were challenged with vir-
ulent PPRV, no clinical signs or high rectal temperatures were
observed in either the recombinant or conventional vaccinated
groups whilst control animals developed severe clinical disease and
were humanely terminated at 8 days post challenge (Fig. 3). Control
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Fig. 2. Characterisation of rescued viruses in confocal microscopy and multistep growth study. (a) Expression of PPRV N, and H proteins and/or GFP with C77 mAb  binding
activity in the PPRV recombinants and parental virus infected cells. VDS cells were infected with viruses at MOI  of 0.01 and ﬁxed 24 h post-infection using 4% paraformaldehyde.
Cells were stained separately with primary antibodies of mouse anti PPRV H (C77) and mouse anti PPRV N (C11) followed by secondary antibody Alexa Fluor 568 goat anti-
mouse  (red). Cell nuclei were stained with DAPI (blue) and GFP autoﬂorescence was  visualised (green). The expression pattern of PPRV N and H proteins were comparable
between the recombinant and parental virus. Wildtype H protein in PPRV Nigeria 75/1, rPPRV + GFP and rPPRV were detected using the C77 mAb whilst H was not detected
using  this antibody in cells infected with rPPRV-C77. The autoﬂorescence of GFP was detected for the rPPRV + GFP virus. (b) Growth kinetics study of recombinant and
parental  PPRVs in cell culture. Multi-step growth curve was  obtained by infecting VDS cells with virus at an MOI  0.01 and grew for different time point and the titre of virus
determined (TCID50).
Table 1
Ct-values obtained from reverse-transcription real-time PCR analysis using the eye swab samples collected from vaccinated and unvaccinated challenged goats.
Treatment group Goat number Ct value
0dpc 2dpc 4dpc 6dpc 8dpc 10dpc 12dpc 14dpc
rPPRV-C77 G1 – – – – – – – –
G2  – – – – – – – –
G3  – – – – – – – –
G4  – – – – – – – –
PPRV  Nig75/1 G7 – – – – – – – –
G8  – – – – – – – –
G9  – – – – – – – –
G10  – – – – – – – –
Control G5  – – 37.54 29.22 24.21 NA NA NA
G6  – – 35.78 26.87 25.15 NA NA NA
G11  – – 38.44 30.45 25.46 NA NA NA
G12  – – 38.64 28.5 27.62 NA NA NA
No Ct-value in real-time PCR is represented as ‘–’; dpc, days post-challenge; NA, not applicable. Ct values more than 40 are considered as negative.




























‘ig. 3. Rectal temperatures of vaccinated (recombinant and parent vaccine virus) a
wice  per day and are presented as the mean values of the four animals in each group
nimals housed with groups one and two following vaccination did
ot seroconvert at 28 days post vaccination. Detection of viral spe-
iﬁc RNA and live virus was observed in the eye swabs of control
nimals during the post challenge period whereas no virus/viral
enome was detected from both the vaccinated groups throughout
ost-challenge period (Tables 1 and 2). The recombinant virus iso-
ated from the PBMCs at 4 and 8 days post vaccination conﬁrmed
hat the mutated C77 mAb  binding site on H protein of rPPRV-C77
ad not been altered or reverted back to its native sequence.
The PPRV H-speciﬁc antibody response on serum collected from
he vaccinated and challenged animals was assessed using the com-
ercially available PPR antibody ELISA kit (BDSL, UK). All animals
ere sero-negative for PPRV speciﬁc antibodies on the day of vac-
ination. Both the recombinant and parental vaccinated animals
ere seen positive for PPRV H-speciﬁc antibodies starting from
ay 8 post-vaccination and reached at peak by two week post-
accination (Fig. 4a). Sera collected during both the vaccination and
hallenge period were subjected to VNT using homologous PPRV
accine strains. On the day of vaccination animals were found to
e negative for PPR speciﬁc antibodies whilst high titre virus neu-
ralising antibodies were detected by second week of vaccination
nd reached at peak (log 4.76–5.31) on day 28 post vaccination, the
ay the animals were challenged, in both groups of vaccinated ani-
als (Fig. 4b and supplementary Table 1). All unvaccinated control
able 2
irus isolation from eye swab samples of vaccinated and unvaccinated challenged goats.
Treatment group Goat number Virus isolation
0dpc 2dpc 4dp
rPPRV-C77 G1 N N N 
G2  N N N 
G3  N N N 
G4  N N N 
PPRV  Nig75/1 G7 N N N 
G8  N N N 
G9  N N N 
G10  N N N 
Control G5  N N Y 
G6  N N Y 
G11  N N Y 
G12  N N Y 
N’ represents no virus isolation, ‘Y’ represents virus isolation and ‘NA’ represents not appaccinated goats upon challenge with virulent PPRV. Temperatures were measured
 standard error. (Data provided for every alternative day during vaccination period).
animals remained negative during this period. Following challenge,
titres of antibodies in both groups one and two remained constant
at two weeks post challenge. No statistically signiﬁcant difference
in neutralising antibody titre was seen between groups one and
two. The unvaccinated animals had developed PPRV speciﬁc neu-
tralising antibodies by the eighth day post-challenge, the day they
were humanely terminated.
4. Discussion
Despite the availability of reverse genetics techniques for other
morbilliviruses, a rescue technique for PPRV was lacking until suc-
cessful rescue was reported almost simultaneously [21,22]. Initial
attempts to rescue a ﬁeld isolate of PPRV were unsuccessful and
following extensive investigation, the highly GC rich region of the
genome was  believed to be a potential bottle neck for viable virus
rescue [23]. To overcome potential sequence errors introduced by
the techniques involved in stitching together a full length DNA copy
of the viral genome artiﬁcial DNA synthesis was applied to gener-
ate error free plasmids for virus rescue. The insertion of a novel
transcription cassette within the genome facilitated ease of virus
rescue and potential future evaluation of positive marker genes
for DIVA activity. The mutation of residues within H to investigate
the potential for a negative marker vaccine demonstrated H gene
c 6dpc 8dpc 10dpc 12dpc 14dpc
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
N N N N N
Y Y NA NA NA
Y Y NA NA NA
Y Y NA NA NA
Y Y NA NA NA
licable.
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Fig. 4. Detection of PPR speciﬁc antibodies in vaccinated and challenged goats.
(a)  Mean percent inhibition values of PPRV H-speciﬁc antibody responses in ani-
mals vaccinated with the wildtype vaccine, rPPRV-C77 and unvaccinated animals
as  determined by c-H ELISA. Serum was collected at days 0, 6, 8, 10, 12, 15, 22 and 28
days post vaccination (dpv) as well as on day 8 post-challenge (dpc). (b) Mean virus
























cy VNT. Serum samples were analysed for 0, 8, 15 and 28 days post-vaccination and
 and 14 days post-challenge. * Represents for the unavailability of serum samples
rom unvaccinated animals due to their sacriﬁce on 8 days post-challenge.
unctionality and stability of the introduced mutations. Likewise,
n vitro the incorporation of eGFP as a novel transcription cassette
nd novel restriction enzyme sites in the UTRs of each gene was tol-
rated. Neither approach affected in vitro growth compared to the
arental strain. Both approaches had been investigated previously
or RPV where in vitro development of positively and negatively
arked vaccines has been assessed [15,24–26]. Following rescue
nd passage, CPE observed with both the recombinant viruses were
imilar to that of the parental virus. The cellular distribution of N
nd H proteins in recombinant viruses were the same as in cells
nfected with parental virus and were as expected for PPRV.
Recent studies reporting the rescue of PPRV expressing GFP
r FMDV VP1 proteins have been limited to in vitro data in their
ssessment for the protective efﬁcacy against rescued PPR viruses
22,27]. In the present study in vivo data has been generated to
emonstrate that the recombinant virus is able to generate ade-
uate protection from virulent challenge in the natural host for
PRV, small ruminants. In vivo assessment is a necessary prerequi-
ite to determining the utility of recombinant versions of vaccines
rior to further development and licencing in the ﬁeld. Both the
arental and mutated (rPPRV-C77) Nigeria 75/1 vaccines provided
omplete protection against a lethal dose of PPRV challenge. None 33 (2015) 465–471
of the animals in either vaccinated group showed any evidence
of PPR disease and survived the challenge with pathogenic PPRV.
Furthermore, there was  no transmission of vaccine virus to in-
contact unvaccinated control animals housed with the vaccinated
animals during the 4 week period post vaccination demonstrat-
ing that both the parent and mutated (rPPRV-C77) vaccines are
highly unlikely to transmit between animals and potentially revert
to virulence in the ﬁeld. Indeed, none of the control animals sero-
converted and all developed clinical disease following challenge.
High titre PPRV speciﬁc serological responses were demonstrated
28 days post-vaccination by both VNT and ELISA for all vaccinated
animals. Although the rPPRV-C77 vaccine virus was  indistinguish-
able from the parent vaccine strain in its ability to protect animals,
DIVA potential was not fulﬁlled with the mutations applied to
residues within H protein using the current H cELISA. Previous
studies with other viral vaccines such as RPV [15], Newcastle dis-
ease virus [28] and classical swine fever virus [29] vaccines have
postulated that epitope deletion may represent an efﬁcient mech-
anism to generate DIVA vaccines. However, in the current study
although epitope mutation prevented binding of C77 mAb in vitro
it was  not sufﬁcient to enable DIVA in vivo. As mapped by phase
display screening technique, six critical residues were implicated
for C77 binding. Mutation of three critical residues from wild type
to alanines (R547, S549 and S550) prevented the binding of mAb
to the virus in immunoﬂuorescence studies. These mutations were
seen to be stable after several passages of rescued virus in cell cul-
ture. Therefore, to keep the changes minimal to the parent virus,
we had not mutated other three critical residues (Y540, I542 and
Y543) and gone forward for the animal experiment assuming for
similar results as in vitro. It is likely that these three un-mutated
critical residues are additionally involved for the binding and we
are looking into this possibility to further explore mutation of the
C77 binding region by altering these residues. Another approach
is currently underway to further develop a PPRV DIVA test using
synthetic peptides speciﬁc to the C77 epitope region. If successful
to develop a DIVA test, certainly, the provision of a recombinant
DIVA PPRV vaccine would be a great boon in the less developed
regions of the world where PPRV represents a major obstacle to
the development and maintenance of subsistence farming.
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